New Educational Resource: Targeted Therapy Approval Timeline

As an internationally recognized center for research and clinical care of patients with blood cancers, who conduct more clinical research studies than our regional peers, we believe in the importance of patient education. To this end we have created a Targeted Therapy Approval subsection for our websites Clinical Trials page.

This page will be updated with information about the newest, next generation of targeted therapies as they receive FDA Breakthrough Therapy Designation, and FDA approval. It is intended as an educational resource.

If you have any questions please contact Robert Birchard at rob2052@med.cornell.edu or 212-746-2919.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s